Coronary Stenting in Patients With Small Coronary Arteries at High Risk of Bleeding: Onyx ONE Clear
暂无分享,去创建一个
M. Price | G. Stone | T. Nazif | S. Windecker | R. Mehran | D. Kandzari | G. Sardella | A. Kirtane | H. Liew | S. Worthley | C. Tamburino | A. Latib | H. Golwala | E. Kedhi | T. Lung | T. Tolleson | D. Spriggs | N. Kander | R. Moreno | Cecile Mahoney | Daniel I. Simon
[1] R. Virmani,et al. Thromboresistance and endothelial healing in polymer-coated versus polymer-free drug-eluting stents: Implications for short-term dual anti-platelet therapy. , 2020, International journal of cardiology.
[2] M. Price,et al. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients , 2020, Circulation. Cardiovascular interventions.
[3] Deepak L. Bhatt,et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.
[4] M. Price,et al. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. , 2020, The New England journal of medicine.
[5] G. Stone,et al. Relationship Between Stent Diameter, Platelet Reactivity, and Thrombotic Events After Percutaneous Coronary Artery Revascularization. , 2019, The American journal of cardiology.
[6] A. Zaman,et al. Clinical outcomes in unselected patients treated with the PROMUS Element platinum‐chromium, everolimus‐eluting stent: Final five‐year results from the PE PROVE Study , 2018, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[7] Volkmar Falk,et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.
[8] G. Mintz,et al. The OCT-ORION Study: A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-Eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss , 2018, Circulation. Cardiovascular interventions.
[9] A. Yeung,et al. Impact of Stent Size Selection on Acute and Long-Term Outcomes After Drug-Eluting Stent Implantation in De Novo Coronary Lesions , 2017, Circulation. Cardiovascular interventions.
[10] Shigeru Saito,et al. First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter. , 2017, JACC. Cardiovascular interventions.
[11] M. Stoel,et al. Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial. , 2016, American heart journal.
[12] Jeroen J. Bax,et al. Third universal definition of myocardial infarction. , 2012, Global heart.
[13] P. Serruys,et al. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everol , 2011, JACC. Cardiovascular interventions.
[14] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[15] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[16] J. López-Sendón,et al. Clinical impact of in-stent late loss after drug-eluting coronary stent implantation. , 2007, European heart journal.
[17] G. Breithardt,et al. Relationship of Late Loss in Lumen Diameter to Coronary Restenosis in Sirolimus-Eluting Stents , 2005, Circulation.
[18] Fernando Alfonso,et al. Coronary stenting versus balloon angioplasty in small vessels: a meta-analysis from 11 randomized studies. , 2004, Journal of the American College of Cardiology.